A VC firm based in Paris invests primarily in seed/series A with significant follow-on capability.

The firm is now investing with two funds; the first fund is dedicated to investing in companies based in the Paris region across various sectors (digital, deeptech, life science), while the second fund is dedicated to investing in Digital Health companies in Western Europe. The firm generally invests between 0.3-1.5M EUR in the initial investment, and can invest up to 2-5M EUR overall in a company, and will invest in up to 10 companies a year.

The firm invests differently from their two current funds :

– The first fund is sector agnostic, and will invest in Life Science (therapeutics, diagnostics, devices and digital health companies) in the Paris region.
– The second fund covering Western Europe is focused primarily on digital health, due to the strategic interest of the fund investors in this area (several healthcare companies)

The firm can lead or co-invest, and do frequently lead. They will take a board seat in any case – the firm is an active investor providing hands-on support to its portfolio company (Strategy, HR, Financing, …).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in 2020 and based in USA is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with check sizes between 5 – 10 million USD. The firm prefers to lead the financing rounds but is open to co-investing. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A life science venture capital arm of a large corporation is interested in therapeutic, medical device, diagnostic, and digital health technologies. The firm usually participates in Seed to series C financing rounds with check sizes between $500K – 2M USD. The firm is open to both leading and co-investing and is aiming to make 15 investments in the next 12 months. The firm is open to global opportunities.

The firm is open to considering innovative technologies that address unmet medical needs in therapeutics, diagnostics, medical devices, and digital health. The firm’s greatest interest lies in the biotech and diagnostic sector in which the firm have the strongest expertise. For medical devices and diagnostics, the firm is open to any subsectors but is most interested in AI-based diagnostics and innovative genomics applications. The firm is open to any indication area including oncology, CNS diseases and rare diseases.

The firm seeks to work with companies with a sound business model and great execution, but will mainly focus on the merit of technologies and the team when working with very early-stage companies. The firm considers itself to be an active investor and will take a board seat depending on the cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA-based fund invests in both external venture capital funds, and also has a fund of $150 million from which to make direct investments in early stage companies. The firm focuses on investing in startups with some connection to universities near the fund but also makes some investments into outside startups.  Initial investments are typically made at an early stage, and most are from $250,000-1 million; the firm also makes follow-on investments. The firm invests primarily in the US and also considers opportunities in Canada.

The firm invests in a wide variety of technology sectors; in the life sciences, the fund is focused on diagnostics, medical devices, and innovative areas of digital health.  The firm is opportunistic and will consider life science innovations broadly; areas of high interest include cancer care, AI, machine learning, clinical decision support systems, and imaging.  The firm will consider investing at a very early stage of development.

The firm focuses on startups with a connection to local universities, and the organization has an additional innovation capital program for developing innovative technology in the US Midwest, including resources for incubating and accelerating new life science startups.  However, the firm also invests in startups that have no prior connection to such universities.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA focuses exclusively on early stage and seed investments in medical device companies. The firm provides seed, first, or second round of financing, typically in equity. The initial investment in a company ranges from $250K to $3M, with follow-on financing rounds. Accordingly, the firm invests between $2-6M over the life of an investment. The firm typically invests in companies that are based in the US, but may consider exceptional opportunities abroad. The firm is actively seeking new investment opportunities.

The firm is specifically looking for medical devices that address cardiovascular, orthopedic indications. The firm has no clinical requirements and will invest in design stage. The product must be based on strongly protected IP.

The firm prefers to invest in companies that are not looking to develop their own sales team, but rather developing a technology that can be sold at a healthy premium to a company which already has the requisite sales and marketing teams in place. The firm generally takes a board seat, but is not a requirement. In addition, the firm prefers to assume a role on the company’s scientific advisory board. The firm is looking for companies with a strong and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture arm of a company specializing in infection prevention technology, primarily in the hospital setting, is interested in strategic investments and acquisitions, spanning benchtop proof of concept to businesses selling products that are on the market. Within the area of infection prevention and control, The firm will consider digital health, diagnostics and medical device technologies that relate to infection, but will not invest in pharmaceutical therapeutics. Investments can range from less than $1M, up to enterprise scale acquisitions. The firm will invest globally.

The firm is only interested in digital health, diagnostics and medical device technologies that address infection prevention and control, with a focus on healthcare acquired infection. These technologies can include track and trace, contact tracing, prevention and predictive technologies, diagnosis, identification of best treatments and non-drug intervention, among others.

The firm will only make strategic investments that align with the firm. The firm is an active investor, and will typically take a board seat after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital / private equity firm headquartered in China manages both  US and RMB denominated funds. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage, and seeks opportunities globally.

The firm invests in pharmaceuticals and Class II medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid development stage companies. The firm focuses on unmet medical needs with a China market potential.

The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.